KEAP1 and neoplasm: To test this hypothesis, we leveraged the finding that tumours with constitutively active NRF2, due to mutation in the negative regulator Keap1, have metabolic vulnerabilities that arise from their high antioxidant production (Romero et al., 2017), including dependency of glutamine (Romero et al., 2017) and a general dependency on exogenous non-essential amino acids (NEAA) including asparagine (LeBoeuf et al., 2020).